Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.

Dummer, Reinhard, Prince, Henry M, Whittaker, Sean, Horwitz, Steven M, Kim, Youn H, Scarisbrick, Julia, Quaglino, Pietro, Zinzani, Pier Luigi, Wolter, Pascal, Eradat, Herbert, Pinter-Brown, Lauren, Sanches, Jose A, Ortiz-Romero, Pablo L, Akilov, Oleg E, Geskin, Larisa, Huen, Auris, Walewski, Jan, Wang, Yinghui, Lisano, Julie, Richhariya, Akshara, Feliciano, Joseph, Zhu, Yanyan, Bunn, Veronica, Little, Meredith, Zagadailov, Erin, Dalal, Mehul R and Duvic, Madeleine (2020) Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. European journal of cancer (Oxford, England : 1990), 133. pp. 120-130. ISSN 1879-0852. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://www.journals.elsevier.com/european-journal...

Abstract

BACKGROUND

Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-cell lymphoma treated with prior systemic therapy based on improved response rates and progression-free survival with brentuximab vedotin (1.8 mg/kg once every 3 weeks; ≤16 cycles) versus physician's choice (methotrexate/bexarotene; ≤48 weeks) in the phase III ALCANZA study. Quality of life (QoL) in ALCANZA patients was also examined.

METHODS

QoL measures in ALCANZA were based on the Skindex-29, Functional Assessment of Cancer Therapy-General (FACT-G) and European QoL 5-dimension (EQ-5D) questionnaires.

RESULTS

Mean maximum reduction from the baseline Skindex-29 symptom domain score (key secondary end-point) was greater with brentuximab vedotin than physician's choice (-27.96 versus -8.62); the difference, -18.9 (95% confidence interval -26.6, -11.2; adjusted p < 0.001), exceeded the study-defined minimally important difference (9.0-12.3). Mean changes from baseline to end-of-treatment visit total FACT-G scores were similar with brentuximab vedotin and physician's choice (0.15 versus -2.29). EQ-5D changes were also comparable between arms. Among brentuximab vedotin-treated patients with peripheral neuropathy (PN), mean maximum reduction in Skindex-29 symptom domain was -35.54 versus -11.11 in patients without PN. PN had no meaningful effect on FACT-G and EQ-5D QoL scores.

CONCLUSIONS

In summary, brentuximab vedotin produced superior reductions in symptom burden compared with physician's choice, without adversely impacting QoL. QoL was unaffected by the presence of PN in brentuximab vedotin-treated patients.

CLINICAL TRIAL REGISTRATION

NCT01578499.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: QU Biochemistry
QV Pharmacology
QZ Pathology. Oncology
WH Haemic and lymphatic systems. Haematology
WR Skin. Dermatology
Divisions: Planned IP Care > Oncology and Clinical Haematology
Related URLs:
Depositing User: Jamie Edgar
Date Deposited: 18 Jun 2020 11:23
Last Modified: 18 Jun 2020 11:23
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3179

Actions (login required)

View Item View Item